HRD-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER

Clinical trials for HRD-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER explained in plain language.

Never miss a new study

Get alerted when new HRD-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER trials appear

Sign up with your email to follow new studies for HRD-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Targeted drug duo challenges standard chemo in advanced breast cancer fight

Disease control Ongoing

This study compares a new approach using two targeted oral medications against standard chemotherapy for advanced breast cancer that has specific genetic features. After initial chemotherapy, half the participants switch to the targeted drug combination as long-term maintenance t…

Matched conditions: HRD-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER

Phase: PHASE3 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control

Last updated Mar 30, 2026 14:33 UTC

HRD-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER

Get alerted when new HRD-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER trials appear

Targeted drug duo challenges standard chemo in advanced breast cancer fight